Medisafe 1 Technologies Corp. seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. The company’s patented technology is a medical assembly with a locking mechanism that is intended to ensure that a substance cannot be released from a hypodermic needle without positive pre-matching between the substance and its intended patient.
The company today announced positive developments relating to the production of a prototype of its locking device technology. The prototype has successfully passed Medisafe 1 Technologies’ preliminary testing phase. The tests confirm the potential of the prototype to significantly reduce preventable drug-related injuries in hospitals.
Medisafe’s patented locking device works in conjunction with a bar-code reader and database system. The device uses a barcoded system to electronically confirm whether the syringe held by a medical practitioner contains the correct medication and dosage that has been prescribed to a particular patient, before allowing that medication to be physically administered.
There is a definite market for Medisafe’s device. Medication administration errors in hospitals cause 400,000 preventable drug-related injuries and 70,000 deaths each year. The company estimates that the total potential market for its patented technologies could exceed $1 billion per year.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment